Search
Research
Outcomes of rheumatic fever in Uganda: a prospective cohort studyRheumatic heart disease is the largest contributor to cardiac-related mortality in children worldwide. Outcomes in endemic settings after its antecedent illness, acute rheumatic fever, are not well understood. We aimed to describe 3-5 year mortality, acute rheumatic fever recurrence, changes in carditis, and correlates of mortality after acute rheumatic fever.
Research
Ending rheumatic heart disease in Australia: the evidence for a new approachThe RHD Endgame Strategy: the blueprint to eliminate rheumatic heart disease in Australia by 2031 (the Endgame Strategy) is the blueprint to eliminate rheumatic heart disease (RHD) in Australia by 2031. Aboriginal and Torres Strait Islander people live with one of the highest per capita burdens of RHD in the world.
Research
Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injectionBenzathine penicillin G has been used as monthly deep intramuscular (IM) injections since the 1950s for secondary prevention of acute rheumatic fever and rheumatic heart disease (RHD). Injection frequency and pain are major programmatic barriers for adherence, prompting calls for development of better long-acting penicillin preparations to prevent RHD.
News & Events
Trans-Tasman partnership to tackle rheumatic heart diseaseResearchers at The Kids Research Institute Australia have begun a comprehensive research project into vaccines aimed at tackling rheumatic fever.
Research
Public health and economic perspectives on acute rheumatic fever and rheumatic heart diseaseEfforts to eliminate ARF and RHD in Australia over the past decade have so far been unsuccessful, but this can change
Research
Voices behind the statistics: A systematic literature review of the lived experience of rheumatic heart diseaseThis systematic review presents a critical, interpretive analysis of publications that include lived experiences of rheumatic heart disease
Research
How many doses make a difference? An analysis of secondary prevention of rheumatic fever and rheumatic heart diseaseincreased adherence to penicillin prophylaxis is associated with reduced acute rheumatic fever recurrence and a likely reduction in mortality
Research
Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxisThese results indicate that anaphylaxis is not a major cause of adverse reactions to benzathine penicillin G
Research
Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's Northern TerritoryThis study adds to emerging data suggesting increasing importance of iGAS in low- and middle-income settings globally.
Research
Controlling acute rheumatic fever and rheumatic heart disease in developing countries: Are we getting closer?Improved opportunities for the primary prevention of ARF now exist, because of point-of-care antigen tests for Streptococcus pyogenes, and clinical decision...